Suubi+Adherence-Round 2: A study protocol to examine the longitudinal HIV treatment adherence among youth living with HIV transitioning into young adulthood in Southern Uganda.
HIV/AIDS
Uganda
Youth living with HIV
cohort
economic empowerment
sub-Saharan Africa
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
21 01 2021
21 01 2021
Historique:
received:
19
12
2020
accepted:
10
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Youth living with HIV (YLHIV) in Sub-Saharan African (SSA) are less likely to adhere to antiretroviral therapy (ART) and other health-related regimens. As a consequence, YLHIV are not only at risk for health problems and mental health comorbidities, but are also at risk for cognitive deficits, including in areas of memory and executive functioning. The Suubi+Adherence study followed 702 adolescents (10-16 years of age) receiving bolstered standard of care and a family economic empowerment intervention comprising an incentivized youth financial savings account (YSA) augmented with financial literacy training (FLT) and peer mentorship. The study findings pointed to superior short-term viral suppression and positive adolescent health and mental health functioning among participants receiving the intervention. The original group of adolescents who received Suubi+Adherence are now transitioning into young adulthood. This paper presents a protocol for the follow-up phase titled Suubi+Adherence Round 2. The original cohort in Suubi+Adherence will be tracked for an additional five years (2020-2025). Specifically, the long term follow-up will allow to: 1) ascertain the extent to which the short term outcomes identified in the first 6 years of the intervention are maintained as the same group transitions through young adulthood; and 2) address new scientific questions regarding ART adherence; HIV care engagement; protective health behaviors; and the potential of FEE to mitigate the development of HIV-associated neurocognitive disorders in YLHIV. Additionally, the team examines the potential mechanisms through which the observed long-term outcomes happen. Moreover, the Suubi+Adherence-Round 2 adds a qualitative component and extends the cost effectiveness component. Guided by asset and human development theories, Suubi+Adherence-R2 will build on the recently concluded Suubi+Adherence study to conduct one of the largest and longest running studies of YLHIV in SSA as they transition into young adulthood. The study will address new scientific questions regarding long-term ART adherence, HIV care engagement, protective health behaviors, and the potential of FEE to mitigate the development of HIV-associated neurocognitive disorders in YLHIV. The findings may inform efforts to improve HIV care among Uganda's YLHIV, with potential replicability in other low-resource countries. ClinicalTrials.gov , ID: NCT01790373.
Sections du résumé
BACKGROUND
Youth living with HIV (YLHIV) in Sub-Saharan African (SSA) are less likely to adhere to antiretroviral therapy (ART) and other health-related regimens. As a consequence, YLHIV are not only at risk for health problems and mental health comorbidities, but are also at risk for cognitive deficits, including in areas of memory and executive functioning. The Suubi+Adherence study followed 702 adolescents (10-16 years of age) receiving bolstered standard of care and a family economic empowerment intervention comprising an incentivized youth financial savings account (YSA) augmented with financial literacy training (FLT) and peer mentorship. The study findings pointed to superior short-term viral suppression and positive adolescent health and mental health functioning among participants receiving the intervention. The original group of adolescents who received Suubi+Adherence are now transitioning into young adulthood. This paper presents a protocol for the follow-up phase titled Suubi+Adherence Round 2.
METHODS
The original cohort in Suubi+Adherence will be tracked for an additional five years (2020-2025). Specifically, the long term follow-up will allow to: 1) ascertain the extent to which the short term outcomes identified in the first 6 years of the intervention are maintained as the same group transitions through young adulthood; and 2) address new scientific questions regarding ART adherence; HIV care engagement; protective health behaviors; and the potential of FEE to mitigate the development of HIV-associated neurocognitive disorders in YLHIV. Additionally, the team examines the potential mechanisms through which the observed long-term outcomes happen. Moreover, the Suubi+Adherence-Round 2 adds a qualitative component and extends the cost effectiveness component.
DISCUSSION
Guided by asset and human development theories, Suubi+Adherence-R2 will build on the recently concluded Suubi+Adherence study to conduct one of the largest and longest running studies of YLHIV in SSA as they transition into young adulthood. The study will address new scientific questions regarding long-term ART adherence, HIV care engagement, protective health behaviors, and the potential of FEE to mitigate the development of HIV-associated neurocognitive disorders in YLHIV. The findings may inform efforts to improve HIV care among Uganda's YLHIV, with potential replicability in other low-resource countries.
TRIAL REGISTRATION
ClinicalTrials.gov , ID: NCT01790373.
Identifiants
pubmed: 33478469
doi: 10.1186/s12889-021-10202-3
pii: 10.1186/s12889-021-10202-3
pmc: PMC7818782
doi:
Banques de données
ClinicalTrials.gov
['NCT01790373']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Subventions
Organisme : NIMH NIH HHS
ID : P50 MH113662
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD074949
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH118935
Pays : United States
Références
Neurology. 2002 Dec 24;59(12):1944-50
pubmed: 12499488
Pharmacoeconomics. 1996 Jun;9(6):525-34
pubmed: 10160480
Longit Life Course Stud. 2012;3(2):164-172
pubmed: 26473017
Am Psychol. 1998 Feb;53(2):185-204
pubmed: 9491747
AIDS. 2004 Jan 1;18 Suppl 1:S19-25
pubmed: 15075494
AIDS Patient Care STDS. 2003 Dec;17(12):645-56
pubmed: 14746658
Contemp Clin Trials Commun. 2019 Oct 20;16:100463
pubmed: 31872152
Drug Alcohol Depend. 2008 Jan 1;92(1-3):37-47
pubmed: 17644275
J Adolesc Health. 2015 Feb;56(2):127-9
pubmed: 25620297
Psychol Methods. 2002 Jun;7(2):147-77
pubmed: 12090408
Vulnerable Child Youth Stud. 2015 Oct 1;10(4):345-356
pubmed: 27042195
AIDS Care. 2014 Jan;26(1):1-11
pubmed: 23767772
J Consult Clin Psychol. 1974 Dec;42(6):861-5
pubmed: 4436473
JAMA. 1996 Dec 25;276(24):1955-6
pubmed: 8971062
Addiction. 2012 Jul;107(7):1288-96
pubmed: 22236216
Psychol Methods. 2013 Jun;18(2):137-50
pubmed: 23379553
BMC Public Health. 2018 Jun 5;18(1):693
pubmed: 29871619
Am J Manag Care. 1997 Sep;3(9):1387-94
pubmed: 10178487
AIDS Behav. 2009 Oct;13(5):980-8
pubmed: 18839304
Asia Pac J Soc Work Dev. 2019;29(1):59-69
pubmed: 31388222
AIDS. 2011 Mar 13;25(5):561-75
pubmed: 21160410
J Acquir Immune Defic Syndr. 2010 Oct;55(2):221-4
pubmed: 20531208
Clin Infect Dis. 2007 Dec 1;45(11):1492-8
pubmed: 17990233
AIDS Behav. 2017 Apr;21(4):1117-1128
pubmed: 27371136
AIDS. 2002 May 3;16(7):1051-8
pubmed: 11953472
SAHARA J. 2009 Dec;6(4):148-54
pubmed: 20485854
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19485-9
pubmed: 20974976
J Safety Res. 2016 Sep;58:15-20
pubmed: 27620930
Soc Serv Rev. 2009 Sep 1;83(3):453-472
pubmed: 20445763
Drug Alcohol Depend. 1996 Sep;42(1):49-54
pubmed: 8889403
Child Youth Serv Rev. 2014 Aug 1;43:131-137
pubmed: 25067869
Child Youth Serv Rev. 2010 Nov 1;32(11):1585-1590
pubmed: 21076646
J Health Soc Behav. 1996 Sep;37(3):207-20
pubmed: 8898493
Trials. 2018 Aug 6;19(1):423
pubmed: 30081967
Psychol Methods. 2001 Dec;6(4):330-51
pubmed: 11778676
J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71
pubmed: 19282780
J Health Soc Behav. 2000 Mar;41(1):50-67
pubmed: 10750322
Ethn Dis. 1992 Fall;2(4):371-80
pubmed: 1490134
Annu Rev Psychol. 2001;52:1-26
pubmed: 11148297
Soc Sci Med. 2010 Apr;70(7):1002-10
pubmed: 20106578
J Adolesc Health. 2010 Apr;46(4):372-8
pubmed: 20307827
J Black Psychol. 1993 May;19(2):142-154
pubmed: 23529205
AIDS Behav. 2010 Aug;14(4):778-84
pubmed: 19283464
Child Youth Serv Rev. 2014 Sep 1;44:417-421
pubmed: 25136142
Soc Sci Med. 2005 Aug;61(3):555-64
pubmed: 15899315
PLoS One. 2020 Feb 10;15(2):e0228370
pubmed: 32040523
J Adolesc Health. 2018 Jan;62(1S):S29-S36
pubmed: 29273115
AIDS Behav. 2009 Feb;13(1):23-32
pubmed: 18654845
AIDS Behav. 2013 Jan;17(1):86-93
pubmed: 23142855
J Adolesc Health. 2015 Oct;57(4):425-32
pubmed: 26271162
AIDS Care. 2009 Nov;21(11):1381-7
pubmed: 20024714
Sex Transm Infect. 2004 Apr;80(2):82-5
pubmed: 15054164
BMC Womens Health. 2019 Aug 17;19(1):111
pubmed: 31419968
J Am Acad Child Adolesc Psychiatry. 2009 Aug;48(8):810-819
pubmed: 19564801
J Consult Clin Psychol. 2014 Oct;82(5):760-72
pubmed: 24364799
J Child Psychol Psychiatry. 2009 Sep;50(9):1131-8
pubmed: 19298479
J Youth Adolesc. 2016 Mar;45(3):568-80
pubmed: 26602564
BMC Psychiatry. 2014 Nov 22;14:303
pubmed: 25416286
J Dev Behav Pediatr. 2012 May;33(4):298-308
pubmed: 22366661
AIDS Behav. 2013 Sep;17(7):2554-74
pubmed: 22972606
Pediatrics. 2016 Nov;138(5):
pubmed: 27940772
J Adolesc Health. 2012 Mar;50(3):228-35
pubmed: 22325127
Glob Soc Welf. 2015 Jun;2(2):53-64
pubmed: 26636025
Prev Sci. 2016 Jan;17(1):134-43
pubmed: 26228480
Alcohol Res. 2018;39(1):23-30
pubmed: 30557145
Nat Med. 2001 Sep;7(9):1016-20
pubmed: 11533704
Future Virol. 2015;9(10):921-929
pubmed: 25983853
Stat Methods Med Res. 2007 Jun;16(3):259-75
pubmed: 17621471
AIDS Behav. 2010 Dec;14(6):1294-301
pubmed: 20532605
J Int AIDS Soc. 2013 Jun 18;16:18593
pubmed: 23782478
Am J Orthopsychiatry. 2015 Sep;85(5S):S14-21
pubmed: 26460710
AIDS Behav. 2010 Dec;14(6):1340-6
pubmed: 20809380
Drug Alcohol Depend. 1999 Jun 1;55(1-2):91-103
pubmed: 10402154
PLoS One. 2009 Nov 19;4(11):e7898
pubmed: 19936066
AIDS Care. 2007 May;19(5):658-65
pubmed: 17505927
Vulnerable Child Youth Stud. 2019;14(2):181-190
pubmed: 31149021
AIDS. 2010 May 15;24(8):1153-62
pubmed: 20299959
Glob Soc Welf. 2014 Mar 1;1(1):9-24
pubmed: 24999449
J Child Adolesc Ment Health. 2010 Jun;22(1):25-34
pubmed: 25859697
J Adolesc Health. 2009 Aug;45(2):133-41
pubmed: 19628139
AIDS. 2001 Jun 15;15(9):1181-3
pubmed: 11416722
J Adolesc Health. 2008 Jan;42(1):102-4
pubmed: 18155037
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S123-6
pubmed: 17133195
Brain Cogn. 2000 Jun-Aug;43(1-3):49-52
pubmed: 10857661
AIDS Behav. 2016 Nov;20(11):2700-2708
pubmed: 27098408
J Stud Alcohol Suppl. 2002 Mar;(14):101-17
pubmed: 12022716
AIDS Care. 2012;24(10):1226-32
pubmed: 22375826
J Pediatr Infect Dis. 2018 Sep;13(3):185-201
pubmed: 30100780
Arch Clin Neuropsychol. 1993 Mar;8(2):123-35
pubmed: 14589670
Child Youth Serv Rev. 2010 Dec 1;32(12):1704-1710
pubmed: 20948971
AIDS Behav. 2017 Jan;21(1):129-140
pubmed: 26874846
Cochrane Database Syst Rev. 2016 Apr 29;4:CD009794
pubmed: 27128768
Nat Neurosci. 2003 Mar;6(3):309-15
pubmed: 12548289
Technol Health Care. 2010;18(2):137-44
pubmed: 20495253
Lancet. 2006 Apr 22;367(9519):1367-9
pubmed: 16631916
AIDS Care. 2016 Mar;28 Suppl 2:83-91
pubmed: 27392003
AIDS Behav. 2018 Nov;22(11):3763-3772
pubmed: 29846836
AIDS. 2005 Aug 12;19(12):1243-9
pubmed: 16052078
J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):145-152
pubmed: 30865180
Ann Intern Med. 2003 Nov 18;139(10):810-6
pubmed: 14623618
Am J Prev Med. 1998 Jul;15(1):54-9
pubmed: 9651639
Int J STD AIDS. 2006 Nov;17(11):713-7
pubmed: 17062170
Lancet. 2007 Apr 14;369(9569):1302-1313
pubmed: 17434406
Lancet Psychiatry. 2014 Dec;1(7):569-76
pubmed: 26361316
AIDS Educ Prev. 1993 Winter;5(4):340-51
pubmed: 8297713
Int J Gynaecol Obstet. 2016 Jan;132(1):1-3
pubmed: 26613822
AIDS Care. 2012;24(8):953-62
pubmed: 22519762
Curr Opin HIV AIDS. 2016 Sep;11(5):477-486
pubmed: 27272537
Soc Serv Rev. 2014 Dec;88(4):658-694
pubmed: 25525282
Clin Infect Dis. 2002 Apr 15;34(8):1115-21
pubmed: 11915001
AIDS Care. 2016;28(3):273-82
pubmed: 26548549
Neuropsychol Rev. 2009 Jun;19(2):152-68
pubmed: 19462243
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
HIV Clin Trials. 2008 Sep-Oct;9(5):298-308
pubmed: 18977718
Afr J AIDS Res. 2004 May;3(1):33-41
pubmed: 25874981
AIDS. 2005 Jan 3;19(1):1-14
pubmed: 15627028
J Adolesc Health. 2004 Jan;34(1):3-26
pubmed: 14706401
J Child Psychol Psychiatry. 2012 Apr;53(4):363-70
pubmed: 21883206
AIDS. 2006 Oct 24;20(16):2116-8
pubmed: 17053359
Addiction. 2002 Sep;97(9):1183-94
pubmed: 12199834
Am J Public Health. 2010 Mar;100(3):483-8
pubmed: 20075323
Prev Sci. 2012 Jun;13(3):288-99
pubmed: 22246429
J Clin Child Adolesc Psychol. 2014;43(3):428-41
pubmed: 24787707
J Nerv Ment Dis. 1992 Feb;180(2):101-10
pubmed: 1737971
JAMA. 2008 Aug 6;300(5):520-9
pubmed: 18677024
Arch Sex Behav. 2013 May;42(4):523-32
pubmed: 22576250
Am J Epidemiol. 2011 Aug 1;174(3):253-60
pubmed: 21749974
J Epidemiol Community Health. 2013 Mar;67(3):225-30
pubmed: 23410851
J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):281-8
pubmed: 14600572
J Behav Med. 2007 Oct;30(5):359-70
pubmed: 17588200
Am J Public Health. 2007 Jun;97(6):1096-101
pubmed: 17463379
Pediatr Infect Dis J. 2012 Jun;31(6):592-8
pubmed: 22592486
Annu Rev Public Health. 2005;26:399-419
pubmed: 15760295
J Policy Anal Manage. 2018 Summer;37(3):602-629
pubmed: 30122799
J Am Acad Child Adolesc Psychiatry. 2005 Aug;44(8):728-47
pubmed: 16034275
J Urban Health. 2011 Jun;88 Suppl 2:S318-40
pubmed: 21340662
PLoS One. 2019 Dec 31;14(12):e0226809
pubmed: 31891601
J Adolesc Health. 2012 Apr;50(4):346-52
pubmed: 22443837